News | November 10, 2024
Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr
Q2 FY25 Total Income was at Rs. 85.4 crore
Q2 FY25 Total Income was at Rs. 85.4 crore
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Aims to achieve CDMO sales of US$ 400 million by 2028
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
Subscribe To Our Newsletter & Stay Updated
